Design Therapeutics (DSGN) Cash from Investing Activities (2020 - 2026)

Design Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at $15.1 million in Q2 2026.

• Cash from Investing Activities for Q2 2026 came in at $15.1 million, down 25.15% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.4 million (down 90.02% YoY), and the FY2025 annual result was $22.9 million, down 47.87% from the prior year.
• Cash from Investing Activities rose to $15.1 million in Q2 2026, from -$7.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $27.3 million in Q2 2024 and troughed at -$157.0 million in Q2 2022.
• A 5-year average of -$5.2 million and a median of $6.0 million in 2023 frame the typical range for Cash from Investing Activities.
• The widest annual swing landed in 2022, when Cash from Investing Activities slumped 1157.22%; it then soared 4666.43% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$1.1 million in 2022, then jumped by 626.04% to $5.6 million in 2023, then plunged by 67.02% to $1.8 million in 2024, then sank by 732.26% to -$11.6 million in 2025, then soared by 229.98% to $15.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $15.1 million in Q2 2026, -$7.6 million in Q1 2026, and -$11.6 million in Q4 2025.